Index of /pdf

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[ ]2013_AAN_CognitionPRO_Poster.pdf2016-01-26 23:28 510K 
[ ]AAN2013LaRocca.pdf2016-01-26 23:28 5.2M 
[ ]ABORAppointment.pdf2016-01-26 23:28 95K 
[ ]AMAwarfarin_brochure.pdf2016-01-26 23:28 597K 
[ ]Annual report final 2006.pdf2016-01-26 23:28 3.5M 
[ ]Annual report final 2007.pdf2016-01-26 23:28 578K 
[ ]AnthonyPSSW.pdf2016-01-26 23:28 391K 
[ ]BSmithPSSW.pdf2016-01-26 23:28 3.5M 
[ ]BicycleFriendly.pdf2016-01-26 23:28 289K 
[ ]BronsteinPSSW.pdf2016-01-26 23:28 1.7M 
[ ]BudnitzPSSW.pdf2016-01-26 23:28 837K 
[ ]C-PathBoardCOIPolicy.pdf2016-01-26 23:28 91K 
[ ]C-PathCEONewsRelease.pdf2016-01-26 23:28 270K 
[ ]C-PathCOIPoilicy.pdf2016-01-26 23:28 209K 
[ ]C-PathEmployeeCOI.pdf2016-01-26 23:28 33K 
[ ]CAMD Overview.pdf2016-01-26 23:28 275K 
[ ]CAMDPage.pdf2016-01-26 23:28 181K 
[ ]CAMD Presentation for Website.pdf2016-01-26 23:28 189K 
[ ]CAMDSummary.pdf2016-01-26 23:28 213K 
[ ]CAMDWorkScope.pdf2016-01-26 23:28 2.0M 
[ ]CERT.pdf2016-01-26 23:28 369K 
[ ]CPI2008AnnualReport.pdf2016-01-26 23:28 2.1M 
[ ]CPIBoardCOIPolicy.pdf2016-01-26 23:28 34K 
[ ]CPIEmployeeCOIPolicy.pdf2016-01-26 23:28 48K 
[ ]CPIFDAMOU2010.pdf2016-01-26 23:28 173K 
[ ]CPIInstitutionalCOIPolicy.pdf2016-01-26 23:28 255K 
[ ]CPTR-a-new-paradigm-for-TB-drug-development-10_11.pdf2016-01-26 23:28 1.3M 
[ ]CPTR 2010 MARCH.pdf2016-01-26 23:28 702K 
[ ]CPTR Statement of Principles - 3 14 10.pdf2016-01-26 23:28 551K 
[ ]CPTR Statement of Principles - FINAL.pdf2016-01-26 23:28 141K 
[ ]CPTRWorkScope2010.pdf2016-01-26 23:28 1.3M 
[ ]CPath2010AnnualReport.pdf2016-01-26 23:28 2.5M 
[ ]CPath2012AnnualReport.pdf2016-01-26 23:28 2.8M 
[ ]CPath_990.pdf2016-01-26 23:28 1.3M 
[ ]CarletonPSSW.pdf2016-01-26 23:28 3.9M 
[ ]ChamberlainPSSW.pdf2016-01-26 23:28 521K 
[ ]CoalitionFactSheet.pdf2016-01-26 23:28 588K 
[ ]CollaborativeNeutralModel2.pdf2016-01-26 23:28 162K 
[ ]Conference Agenda FINAL.pdf2016-01-26 23:28 2.2M 
[ ]CrowleyPSSW.pdf2016-01-26 23:28 508K 
[ ]DRAFT CPTR.pdf2016-01-26 23:28 421K 
[ ]DavisPSSW.pdf2016-01-26 23:28 854K 
[ ]Dispose_a_med_brochure.pdf2016-01-26 23:28 279K 
[ ]EMAreport.pdf2016-01-26 23:28 170K 
[ ]ElixhauserPSSW.pdf2016-01-26 23:28 8.8M 
[ ]FDADraftDDTools.pdf2016-01-26 23:28 190K 
[ ]FDADraftGuidanceCoDevelopment.pdf2016-01-26 23:28 94K 
[ ]FDAEMEA.pdf2016-01-26 23:28 107K 
[ ]FDA_MOU.pdf2016-01-26 23:28 1.5M 
[ ]FDAcriticalpathinitiativeinfluenceonnewdrugdevelopmentWoodcockWoosley.pdf2016-01-26 23:28 129K 
[ ]FeasibilityDocument.pdf2016-01-26 23:28 115K 
[ ]ForrestPSSW.pdf2016-01-26 23:28 210K 
[ ]GoodsaidPSTCsynthesisgoalschallengesaccomplishments.pdf2016-01-26 23:28 144K 
[ ]GoodsaidStrategicpathsbiomarkerqualification.pdf2016-01-26 23:28 200K 
[ ]GrossPSSW.pdf2016-01-26 23:28 903K 
[ ]ISPOR2013_DWG_QualDev_poster.pdf2016-01-26 23:28 217K 
[ ]ISPOR2013_DWG_Translatability_Poster.pdf2016-01-26 23:28 242K 
[ ]ISPOR_June_2012_Workshop.pdf2016-01-26 23:28 2.4M 
[ ]ISPOR_May_2013_Workshop.pdf2016-01-26 23:28 1.2M 
[ ]InstitutionalCOIPolicy.pdf2016-01-26 23:28 114K 
[ ]JacobsPSSW.pdf2016-01-26 23:28 1.8M 
[ ]KirkendallPSSW.pdf2016-01-26 23:28 1.8M 
[ ]LieuPSSW.pdf2016-01-26 23:28 436K 
[ ]McMahonPSSW.pdf2016-01-26 23:28 164K 
[ ]MurphyPSSW.pdf2016-01-26 23:28 4.9M 
[ ]MyMedsList.pdf2016-01-26 23:28 138K 
[ ]NCDEU2013_DWG_QualDev_poster.pdf2016-01-26 23:28 225K 
[ ]ONeillPSSW.pdf2016-01-26 23:28 8.7M 
[ ]PMDAReportPSTCtranslation.pdf2016-01-26 23:28 332K 
[ ]PRO-Ball-et-al-2012-PROMH.pdf2016-01-26 23:28 1.1M 
[ ]PRO-Blum-et-al-2012-ISCTM.pdf2016-01-26 23:28 269K 
[ ]PRO-Blum-et-al-2012-PROMH.pdf2016-01-26 23:28 2.1M 
[ ]PRO-Carpenter-et-al-2012-CNS.pdf2016-01-26 23:28 194K 
[ ]PRO-Houle-et-al-2012-ISPOR-EU.pdf2016-01-26 23:28 587K 
[ ]PRO-McCarrier-et-al-2012-ISPOR-EU[1].pdf2016-01-26 23:28 144K 
[ ]PRO2013DDW_Poster.pdf2016-01-26 23:28 196K 
[ ]PRO Consortium's Cognition WG - RFP 22OCT12.pdf2016-01-26 23:28 219K 
[ ]PROWorkshopAgenda.pdf2016-01-26 23:28 388K 
[ ]PROWorkshopRegistrationForm.pdf2016-01-26 23:28 330K 
[ ]PSTC.pdf2016-01-26 23:28 137K 
[ ]PSTC Executive_Director.pdf2016-01-26 23:28 98K 
[ ]PSTCGeneralInfo.pdf2016-01-26 23:28 47K 
[ ]PSTCGeneralInfoNov2010.pdf2016-01-26 23:28 47K 
[ ]PSTCInterestLetter.pdf2016-01-26 23:28 48K 
[ ]PSTCOverview.pdf2016-01-26 23:28 30K 
[ ]PSTC_GeneralInfo_08-08-08.pdf2016-01-26 23:28 40K 
[ ]PSTC_GeneralInfo_08-28-09.pdf2016-01-26 23:28 31K 
[ ]PSTC_Interest_Letter.pdf2016-01-26 23:28 35K 
[ ]PSTC_Interest_Letter1.pdf2016-01-26 23:28 35K 
[ ]PSTC_nephro_VXDS_summary_final.pdf2016-01-26 23:28 87K 
[ ]PSTCworkflowSlidev2.pdf2016-01-26 23:28 75K 
[ ]PharmacometricsDisciplineEnteringIndustrializationPhase.pdf2016-01-26 23:28 264K 
[ ]PressReleaseCDISCInternationalInterchange2011.pdf2016-01-26 23:28 263K 
[ ]QualitativeResearchSummary.pdf2016-01-26 23:28 106K 
[ ]QualitativeResearchSummaryDocumentTemplate.pdf2016-01-26 23:28 151K 
[ ]QuantitativeResearchSummaryDocumentTemplate.pdf2016-01-26 23:28 154K 
[ ]RacoosinPSSW.pdf2016-01-26 23:28 574K 
[ ]ScopingStageSummaryDocumentTemplate.pdf2016-01-26 23:28 156K 
[ ]StockwellPSSW.pdf2016-01-26 23:28 465K 
[ ]TakataPSSW.pdf2016-01-26 23:28 182K 
[ ]WarfarinInteractionsDrugInformaitonCompendiaFDA-ApprovedLabelWarfarinSodium.pdf2016-01-26 23:28 114K 
[ ]WoosleyCossmanDrugdevelopmentFDACriticalPathInitiative.pdf2016-01-26 23:28 146K 
[ ]annualReport2011.pdf2016-01-26 23:28 3.9M 
[ ]brownsteinPSSW.pdf2016-01-26 23:28 5.7M 
[ ]communications_and_public_relations_director.pdf2016-01-26 23:28 369K 
[ ]conference-agenda-2011.pdf2016-01-26 23:28 2.2M 
[ ]ePRO-DevelopmentPrinciplesNewClinicalOutcomeAssessmentInstruments.pdf2016-01-26 23:28 425K 
[ ]ePRO-Eremenco-et-al-2012-ISPOR-EU.pdf2016-01-26 23:28 439K 
[ ]ePRO-Hollen-et-al-2013.pdf2016-01-26 23:28 214K 
[ ]ePRO-MigrationPrinciplesforExistingCOAInstruments.pdf2016-01-26 23:28 478K 
[ ]ePROMcKenzie-2004-ProvingtheeDiaryDividend.pdf2016-01-26 23:28 215K 
[ ]pbm-kiroku-e.pdf2016-01-26 23:28 259K 
[ ]speaker-request-form.pdf2016-01-26 23:28 152K 
Apache/2.4.41 (Ubuntu) Server at c-path.eu Port 443